Details of Disease

General Information of Disease (ID: DISSC4V5)

• Disease Name: Rabies
• Synonyms: lyssa
• Disease Class: 1C82: Rabies
• Definition: Rabies is a viral zoonosis leading to a fatal encephalopathy if not treated.
• Disease Hierarchy:
  DISFYSIV: Virus infection
  DISOE8QI: Infectious disorder of the nervous system
  DISSC4V5: Rabies
• ICD Code:
  ICD-11: ICD-11: 1C82
  Expand ICD-9: 001,002,003,004,005,006,007,008,009,010,011,012,013,014,015,016,017,018,019,020,021,022,023,024,025,026,027,028,029,030,031,032,033,034,035,036,037,038,039,040,041,042,043,044,045,046,047,048,049,050,051,052,053,054,055,056,057,058,059,060,061,062,063,064,065,066,067,068,069,070,071,072,073,074,075,076,077,078,079,080,081,082,083,084,085,086,087,088,089,090,091,092,093,094,095,096,097,098,099,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139
• Disease Identifiers:
  MONDO ID: MONDO_0019173
  MESH ID: D011818
  UMLS CUI: C0034494
  MedGen ID: 48308
  Orphanet ID: 770
  SNOMED CT ID: 14168008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Berirab	DM3W3FP	Approved	NA	[1]
Indirab	DMX48JY	Approved	NA	[1]
Rabies immune globulin	DMF5JQT	Approved	NA	[1]

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rabies vaccine	DMRTQ9N	Phase 3	NA	[2]
Rabies VRVg	DMCCQS1	Phase 3	NA	[2]
VerorabVax	DMGEWDV	Phase 3	Vaccine	[3]
BPL-HRIG	DM798L1	Phase 2/3	Vaccine	[4]
Human anti-rabies mab	DMUUIEK	Phase 2	Monoclonal antibody	[5]
GSK3903133A	DMS0RB4	Phase 1	Vaccine	[6]
SII Rmab	DMKDCTD	Phase 1	Monoclonal antibody	[7]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PAV-612	DM6OJ23	Investigative	NA	[8]
RabiCide	DMQ8EJU	Investigative	NA	[8]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 10 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
EPHB6	TTZEMUY	Strong	Biomarker	[9]
MALT1	TTCI81G	Strong	Biomarker	[10]
PREP	TTNGKET	Strong	Biomarker	[11]
THBS1	TTKI0H1	Strong	Altered Expression	[12]
TLR3	TTD24Y0	Strong	Biomarker	[13]
DUSP5	TTZN92A	Definitive	Biomarker	[14]
GRM2	TTXJ47W	Definitive	Biomarker	[15]
MOG	TTQAFX5	Definitive	Biomarker	[16]
MTM1	TTY2TCU	Definitive	Biomarker	[14]
RAB7A	TTF6WAQ	Definitive	Biomarker	[17]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC26A3	DTN1FMD	Disputed	Genetic Variation	[18]

This Disease Is Related to 33 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
GAS1	OTKJXG52	Disputed	Biomarker	[19]
KPNA4	OTP0EX18	Disputed	Biomarker	[20]
PCBP2	OTXCN9CG	Disputed	Biomarker	[21]
POU3F4	OTKF5AF7	Disputed	Biomarker	[22]
RAB5A	OTFR2KM4	Disputed	Biomarker	[17]
RAB7B	OT60A0E9	Disputed	Biomarker	[17]
SARS1	OTFKXQ1O	Disputed	Biomarker	[23]
SARS2	OTU4T99W	Disputed	Biomarker	[23]
CBFA2T2	OTNOIB23	Strong	Biomarker	[24]
DNLZ	OT48CG1W	Strong	Biomarker	[9]
EGFLAM	OTACZZJ0	Strong	Biomarker	[13]
ENOSF1	OT65D3ZK	Strong	Biomarker	[25]
ERVW-1	OTWV8DXJ	Strong	Biomarker	[26]
LAMP3	OTN0XL3W	Strong	Biomarker	[27]
LSAMP	OTYXVQX2	Strong	Biomarker	[27]
MYOM2	OTD2UOXW	Strong	Biomarker	[28]
OCA2	OTDWIGBF	Strong	Biomarker	[29]
PAEP	OTQA0NV4	Strong	Biomarker	[11]
PPP1R12C	OT9Q86JO	Strong	Biomarker	[24]
PPP1R13B	OTC88VQO	Strong	Biomarker	[24]
PTPN22	OTDCNTC3	Strong	Biomarker	[11]
RECQL4	OT59LSW7	Strong	Biomarker	[25]
RSAD2	OTCA9WCM	Strong	Biomarker	[30]
CH25H	OT9S2BSW	Definitive	Biomarker	[31]
DCD	OTV5PBGJ	Definitive	Biomarker	[32]
ERAL1	OTSH78HD	Definitive	Biomarker	[33]
IFIT2	OTI4EOAR	Definitive	Altered Expression	[34]
NEFH	OTMSCW5I	Definitive	Altered Expression	[35]
PIP5K1C	OT3LPG1R	Definitive	Biomarker	[14]
RNGTT	OT59E0KX	Definitive	Biomarker	[36]
TCEA1	OTBFO594	Definitive	Altered Expression	[37]
TFPT	OTM70AK1	Definitive	Biomarker	[38]
TNIP2	OTDQWTUB	Definitive	Biomarker	[39]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT01339312) Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of Sanofi.
• [4] ClinicalTrials.gov (NCT03264157) Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects. U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of Molecular Targeting Technologies Inc.
• [6] ClinicalTrials.gov (NCT04062669) A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults. U.S. National Institutes of Health.
• [7] Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine. 2012 Nov 26;30(50):7315-20.
• [8] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [9] Functional analysis of Rousettus aegyptiacus "signal transducer and activator of transcription 1" (STAT1).Dev Comp Immunol. 2010 May;34(5):598-602. doi: 10.1016/j.dci.2010.01.004. Epub 2010 Jan 15.
• [10] MALT1 Controls Attenuated Rabies Virus by Inducing Early Inflammation and T Cell Activation in the Brain.J Virol. 2018 Mar 28;92(8):e02029-17. doi: 10.1128/JVI.02029-17. Print 2018 Apr 15.
• [11] Comparative Immunogenicity and Safety Trial of 2 Different Schedules of Single-visit Intradermal Rabies Postexposure Vaccination.Clin Infect Dis. 2019 Aug 16;69(5):797-804. doi: 10.1093/cid/ciy983.
• [12] Deficient Incorporation of Rabies Virus Glycoprotein into Virions Enhances Virus-Induced Immune Evasion and Viral Pathogenicity.Viruses. 2019 Mar 4;11(3):218. doi: 10.3390/v11030218.
• [13] An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers.Vaccine. 2017 Feb 22;35(8):1175-1183. doi: 10.1016/j.vaccine.2016.12.031. Epub 2017 Jan 22.
• [14] Kinome-Wide RNA Interference Screening Identifies Mitogen-Activated Protein Kinases and Phosphatidylinositol Metabolism as Key Factors for Rabies Virus Infection.mSphere. 2019 May 22;4(3):e00047-19. doi: 10.1128/mSphere.00047-19.
• [15] Metabotropic glutamate receptor subtype 2 is a cellular receptor for rabies virus.PLoS Pathog. 2018 Jul 20;14(7):e1007189. doi: 10.1371/journal.ppat.1007189. eCollection 2018 Jul.
• [16] Protection of bats (Eptesicus fuscus) against rabies following topical or oronasal exposure to a recombinant raccoon poxvirus vaccine.PLoS Negl Trop Dis. 2017 Oct 4;11(10):e0005958. doi: 10.1371/journal.pntd.0005958. eCollection 2017 Oct.
• [17] Rabies virus co-localizes with early (Rab5) and late (Rab7) endosomal proteins in neuronal and SH-SY5Y cells.Virol Sin. 2017 Jun;32(3):207-215. doi: 10.1007/s12250-017-3968-9. Epub 2017 Jun 16.
• [18] Characterization of major histocompatibility complex (MHC) DRB exon 2 and DRA exon 3 fragments in a primary terrestrial rabies vector (Procyon lotor).PLoS One. 2010 Aug 10;5(8):e12066. doi: 10.1371/journal.pone.0012066.
• [19] Immunogenicity and relative attenuation of different vaccinia-rabies virus recombinants.Arch Virol. 1996;141(6):1055-65. doi: 10.1007/BF01718609.
• [20] Postgenomics biomarkers for rabiesthe next decade of proteomics.OMICS. 2015 Feb;19(2):67-79. doi: 10.1089/omi.2014.0127. Epub 2015 Jan 22.
• [21] The 3' untranslated region of the rabies virus glycoprotein mRNA specifically interacts with cellular PCBP2 protein and promotes transcript stability.PLoS One. 2012;7(3):e33561. doi: 10.1371/journal.pone.0033561. Epub 2012 Mar 16.
• [22] Comparative detection of rabies RNA by NASBA, real-time PCR and conventional PCR.J Virol Methods. 2011 Aug;175(2):278-82. doi: 10.1016/j.jviromet.2011.05.007. Epub 2011 May 11.
• [23] Feature selection methods for identifying genetic determinants of host species in RNA viruses.PLoS Comput Biol. 2013;9(10):e1003254. doi: 10.1371/journal.pcbi.1003254. Epub 2013 Oct 10.
• [24] Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and -resistant Pneumococcal meningitis: formulated with RVG(29) and Pluronic() P85 unimers.Drug Deliv. 2018 Nov;25(1):1886-1897. doi: 10.1080/10717544.2018.1486473.
• [25] Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.Vaccine. 2020 Jan 22;38(4):897-906. doi: 10.1016/j.vaccine.2019.10.077. Epub 2019 Nov 7.
• [26] Single domain antibody multimers confer protection against rabies infection.PLoS One. 2013 Aug 20;8(8):e71383. doi: 10.1371/journal.pone.0071383. eCollection 2013.
• [27] Comparison of Reverse Transcription Loop-Mediated Isothermal Amplification Method with SYBR Green Real-Time RT-PCR and Direct Fluorescent Antibody Test for Diagnosis of Rabies.Jpn J Infect Dis. 2020 Jan 23;73(1):19-25. doi: 10.7883/yoken.JJID.2019.009. Epub 2019 Aug 30.
• [28] Generation of Monoclonal Antibodies against Variable Epitopes of the M Protein of Rabies Virus.Viruses. 2019 Apr 23;11(4):375. doi: 10.3390/v11040375.
• [29] Interaction of rabies virus P-protein with STAT proteins is critical to lethal rabies disease.J Infect Dis. 2014 Jun 1;209(11):1744-53. doi: 10.1093/infdis/jit829. Epub 2013 Dec 23.
• [30] A naturally occurring antiviral ribonucleotide encoded by the human genome.Nature. 2018 Jun;558(7711):610-614. doi: 10.1038/s41586-018-0238-4. Epub 2018 Jun 20.
• [31] Cholesterol 25-hydroxylase suppresses rabies virus infection by inhibiting viral entry.Arch Virol. 2019 Dec;164(12):2963-2974. doi: 10.1007/s00705-019-04415-6. Epub 2019 Sep 24.
• [32] Transmission of rabies through solid organ transplantation: a notable problem in China.BMC Infect Dis. 2018 Jun 14;18(1):273. doi: 10.1186/s12879-018-3112-y.
• [33] Generation of a novel live rabies vaccine strain with a high level of safety by introducing attenuating mutations in the nucleoprotein and glycoprotein.Vaccine. 2017 Oct 9;35(42):5622-5628. doi: 10.1016/j.vaccine.2017.08.050. Epub 2017 Sep 4.
• [34] Ifit2 Is a Restriction Factor in Rabies Virus Pathogenicity.J Virol. 2017 Aug 10;91(17):e00889-17. doi: 10.1128/JVI.00889-17. Print 2017 Sep 1.
• [35] Overexpression of MAP2 and NF-H Associated with Dendritic Pathology in the Spinal Cord of Mice Infected with Rabies Virus.Viruses. 2018 Mar 6;10(3):112. doi: 10.3390/v10030112.
• [36] A dual-functional priming-capping loop of rhabdoviral RNA polymerases directs terminal de novo initiation and capping intermediate formation.Nucleic Acids Res. 2019 Jan 10;47(1):299-309. doi: 10.1093/nar/gky1058.
• [37] Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.Clin Infect Dis. 2018 Jan 18;66(3):387-395. doi: 10.1093/cid/cix791.
• [38] Ferret badger rabies in Zhejiang, Jiangxi and Taiwan, China.Arch Virol. 2019 Feb;164(2):579-584. doi: 10.1007/s00705-018-4082-5. Epub 2018 Nov 11.
• [39] Regulation of NF-B by the p105-ABIN2-TPL2 complex and RelAp43 during rabies virus infection.PLoS Pathog. 2017 Oct 30;13(10):e1006697. doi: 10.1371/journal.ppat.1006697. eCollection 2017 Oct.